The Evaluation of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies
Clicks: 310
ID: 99874
2007
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
310 views
32 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #5 of 8 articles by views in flora infeksiyon hastalıkları ve klinik mikrobiyoloji dergisi
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Infections remain the major cause of morbidity and mortality among neutropenic patients with hematologic malignancies. As the delay of antibiotic treatment in such patients increases mortalility, it is necessary, after clinical and microbiological assessment and physical examination, to administer empirical antimicrobial agents. The antibiotic must be with high dosage, wide spectrum and bactericidal effect. One hundred thirty three consecutive neutropenic patients with hematologic malignancies were admitted to the Department of Hematology of Karadeniz Technical University Faculty of Medicine between March 2003 and November 2005. A total of 217 febrile neutropenic episodes were treated; 102 febrile episodes with piperacilline-tazobactam plus amikacin, and 91 episodes with cefepime plus amikacin were treated. Microscopically documented infections were found in 18.4%, other clinically documented infections in 27.6%, and fever of unknown origin in 53.9% of the febrile episodes. Piperacilline-tazobactam plus amikacin was successful in 43 of 102 episodes (42.1%), and cefepime plus amikacin was successful in 46 of 91 episodes (50.5%). After modifications, piperacilline-tazobactam plus amikacin success rate was 90.1%, cefepime plus amikacin success rate was 85.7%. The empirical regimen of cefepime plus amikacin was equivalent to piperacillin-tazobactam plus amikacin in febrile adult hematology patients with severe neutropenia (p= 0.266).
| Reference Key |
aydin2007theflora
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | AYDIN, Kemalettin;YILMAZ, Mustafa;SÖNMEZ, Mehmet;AKSOY, Firdevs;YILMAZ, Gürdal;AKDOĞAN, Elif;SÖZEN, Ebru;ÇAYLAN, H. Rahmet;DURMUŞ, Ahmet;SUCU, Nurgun;KÖKSAL, İftihar;OMAY, Serdar Bedii;OVALI, Ercüment; |
| Journal | flora infeksiyon hastalıkları ve klinik mikrobiyoloji dergisi |
| Year | 2007 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.